



Clinical trial results:

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vedolizumab in the Prophylaxis of Intestinal Acute Graft-Versus-Host Disease in Subjects Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Summary

| | |
|--------------------------|-------------------------------------------------------|
| EudraCT number | 2018-002141-11 |
| Trial protocol | HU SE GB NO DE AT PL ES PT BE GR IT RO Outside EU/EEA |
| Global end of trial date | 09 May 2022 |

Results information

| | |
|--------------------------------|---------------------------------------------------------------------------------------------------------------------------|
| Result version number | v2 |
| This version publication date | 12 January 2023 |
| First version publication date | 02 December 2022 |
| Version creation reason | <ul style="list-style-type: none">• Correction of full data set• Correction on MedDRA version used |

Trial information

Trial identification

| | |
|-----------------------|------------------|
| Sponsor protocol code | Vedolizumab-3035 |
|-----------------------|------------------|

Additional study identifiers

| | |
|------------------------------------|-------------|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT03657160 |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|----------------------------------------------------------|
| Sponsor organisation name | Takeda |
| Sponsor organisation address | 40 Landsdowne Street, Cambridge, United States, MA 02139 |
| Public contact | Study Director, Takeda, TrialDisclosures@takeda.com |
| Scientific contact | Study Director, Takeda, TrialDisclosures@takeda.com |

Notes:

Paediatric regulatory details

| | |
|----------------------------------------------------------------------|---------------------|
| Is trial part of an agreed paediatric investigation plan (PIP) | Yes |
| EMA paediatric investigation plan number(s) | EMA-000645-PIP03-18 |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | Yes |

Notes:

Results analysis stage

| | |
|------------------------------------------------------|-------------|
| Analysis stage | Final |
| Date of interim/final analysis | 09 May 2022 |
| Is this the analysis of the primary completion data? | No |

| | |
|----------------------------------|-------------|
| Global end of trial reached? | Yes |
| Global end of trial date | 09 May 2022 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

The objective of this study is to evaluate the efficacy of vedolizumab when added to background aGvHD prophylaxis regimen compared to placebo and background aGvHD prophylaxis regimen on intestinal aGvHD-free survival by Day +180 in participants who receive allo-HSCT as treatment for a hematologic malignancy or myeloproliferative disorder.

Protection of trial subjects:

All study participants were required to read and sign an Informed Consent Form.

Background therapy:

Intestinal acute graft-versus-host disease (aGvHD) prophylaxis regimen.

Evidence for comparator: -

| | |
|-----------------------------------------------------------|------------------|
| Actual start date of recruitment | 06 February 2019 |
| Long term follow-up planned | Yes |
| Long term follow-up rationale | Safety |
| Long term follow-up duration | 12 Months |
| Independent data monitoring committee (IDMC) involvement? | Yes |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|-----------------------|
| Country: Number of subjects enrolled | Canada: 1 |
| Country: Number of subjects enrolled | United States: 109 |
| Country: Number of subjects enrolled | Argentina: 5 |
| Country: Number of subjects enrolled | Brazil: 4 |
| Country: Number of subjects enrolled | Belgium: 10 |
| Country: Number of subjects enrolled | France: 19 |
| Country: Number of subjects enrolled | Germany: 20 |
| Country: Number of subjects enrolled | Italy: 17 |
| Country: Number of subjects enrolled | Austria: 3 |
| Country: Number of subjects enrolled | Greece: 7 |
| Country: Number of subjects enrolled | Hungary: 2 |
| Country: Number of subjects enrolled | Poland: 2 |
| Country: Number of subjects enrolled | Israel: 7 |
| Country: Number of subjects enrolled | Romania: 2 |
| Country: Number of subjects enrolled | Russian Federation: 5 |
| Country: Number of subjects enrolled | Australia: 20 |
| Country: Number of subjects enrolled | Japan: 37 |

| | |
|--------------------------------------|------------------------|
| Country: Number of subjects enrolled | Korea, Republic of: 22 |
| Country: Number of subjects enrolled | Singapore: 4 |
| Country: Number of subjects enrolled | Norway: 10 |
| Country: Number of subjects enrolled | Portugal: 4 |
| Country: Number of subjects enrolled | Spain: 13 |
| Country: Number of subjects enrolled | Sweden: 3 |
| Country: Number of subjects enrolled | Switzerland: 5 |
| Country: Number of subjects enrolled | United Kingdom: 12 |
| Worldwide total number of subjects | 343 |
| EEA total number of subjects | 112 |

Notes:

Subjects enrolled per age group

| | |
|-------------------------------------------|-----|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 1 |
| Adults (18-64 years) | 264 |
| From 65 to 84 years | 78 |
| 85 years and over | 0 |

Subject disposition

Recruitment

Recruitment details:

Participants took part in the study at 95 investigative sites in Canada, United States, Argentina, Brazil, Belgium, France, Germany, Italy, Norway, Portugal, Spain, Sweden, Switzerland, United Kingdom, Austria, Greece, Hungary, Poland, Israel, Romania, Russia, Australia, Japan, Republic of Korea and Singapore from 6 February 2019 to 9 May 2022.

Pre-assignment

Screening details:

Participants undergoing allogeneic hematopoietic stem cell transplantation (Allo-HSCT) were randomized into 1:1 ratio to receive Vedolizumab 300 mg or vedolizumab-matching placebo.

Pre-assignment period milestones

| | |
|------------------------------|-----|
| Number of subjects started | 343 |
| Number of subjects completed | 333 |

Pre-assignment subject non-completion reasons

| | |
|----------------------------|---------------------------------|
| Reason: Number of subjects | Protocol Deviation: 1 |
| Reason: Number of subjects | Adverse event, non-fatal: 1 |
| Reason: Number of subjects | Consent withdrawn by subject: 3 |
| Reason: Number of subjects | Reason not Specified: 5 |

Period 1

| | |
|------------------------------|----------------------------------------|
| Period 1 title | Overall Study (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Double blind |
| Roles blinded | Subject, Investigator, Carer, Assessor |

Arms

| | |
|------------------------------|---------|
| Are arms mutually exclusive? | Yes |
| Arm title | Placebo |

Arm description:

Vedolizumab placebo-matching, intravenous (IV) infusion, once on Day -1 along with background graft-versus-host disease (GvHD) prophylaxis regimen prior to Allo-HSCT and once on Days +13, +41, +69, +97, +125, and +153 post Allo-HSCT.

| | |
|----------------------------------------|-----------------------|
| Arm type | Experimental |
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Vedolizumab placebo-matching intravenous infusion.

| | |
|------------------|--------------------|
| Arm title | Vedolizumab 300 mg |
|------------------|--------------------|

Arm description:

Vedolizumab 300 mg, IV, once on Day -1 along with background graft-versus-host disease (GvHD) prophylaxis regimen prior to Allo-HSCT and once on Days +13, +41, +69, +97, +125, and +153 post Allo-HSCT.

| | |
|----------|--------------|
| Arm type | Experimental |
|----------|--------------|

| | |
|----------------------------------------|-----------------------|
| Investigational medicinal product name | Vedolizumab |
| Investigational medicinal product code | |
| Other name | MLN0002 |
| Pharmaceutical forms | Solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Vedolizumab intravenous infusion.

| Number of subjects in period 1^[1] | Placebo | Vedolizumab 300 mg |
|-----------------------------------------------------|---------|--------------------|
| Started | 165 | 168 |
| Completed | 98 | 116 |
| Not completed | 67 | 52 |
| Unsatisfactory Therapeutic Response | 5 | 3 |
| Adverse event, serious fatal | 33 | 26 |
| Consent withdrawn by subject | 17 | 14 |
| Adverse event, non-fatal | 4 | 6 |
| Protocol Deviation | 3 | - |
| Site Terminated | 1 | - |
| Death (COVID-19-Related) | 1 | - |
| Other Reasons COVID-19-Related | - | 1 |
| Reason not Specified | 3 | 2 |

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: 10 participants from 343 participants were randomized but did not continue the study.

Baseline characteristics

Reporting groups

| | |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|
| Reporting group title | Placebo |
| Reporting group description: Vedolizumab placebo-matching, intravenous (IV) infusion, once on Day -1 along with background graft-versus-host disease (GvHD) prophylaxis regimen prior to Allo-HSCT and once on Days +13, +41, +69, +97, +125, and +153 post Allo-HSCT. | |
| Reporting group title | Vedolizumab 300 mg |
| Reporting group description: Vedolizumab 300 mg, IV, once on Day -1 along with background graft-versus-host disease (GvHD) prophylaxis regimen prior to Allo-HSCT and once on Days +13, +41, +69, +97, +125, and +153 post Allo-HSCT. | |

| Reporting group values | Placebo | Vedolizumab 300 mg | Total |
|-------------------------------------------------------------------------|-----------------|--------------------|-------|
| Number of subjects | 165 | 168 | |
| Age Categorical Units: Subjects | | | |
| Age continuous Units: years arithmetic mean standard deviation | 51.9 ± 14.49 | 50.8 ± 14.41 | - |
| Gender categorical Units: Subjects | | | |
| Male | | | 0 |
| Female | | | 0 |
| Ethnicity (NIH/OMB) Units: Subjects | | | |
| Hispanic or Latino | 9 | 16 | 25 |
| Not Hispanic or Latino | 133 | 133 | 266 |
| Unknown or Not Reported | 23 | 19 | 42 |
| Race (NIH/OMB) Units: Subjects | | | |
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 36 | 29 | 65 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 3 | 5 |
| White | 114 | 121 | 235 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 13 | 15 | 28 |
| Gender Units: Subjects | | | |
| Male | 106 | 103 | 209 |
| Female | 59 | 65 | 124 |

End points

End points reporting groups

| | |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|
| Reporting group title | Placebo |
| Reporting group description: Vedolizumab placebo-matching, intravenous (IV) infusion, once on Day -1 along with background graft-versus-host disease (GvHD) prophylaxis regimen prior to Allo-HSCT and once on Days +13, +41, +69, +97, +125, and +153 post Allo-HSCT. | |
| Reporting group title | Vedolizumab 300 mg |
| Reporting group description: Vedolizumab 300 mg, IV, once on Day -1 along with background graft-versus-host disease (GvHD) prophylaxis regimen prior to Allo-HSCT and once on Days +13, +41, +69, +97, +125, and +153 post Allo-HSCT. | |

Primary: Intestinal aGvHD-Free Survival After Allo-HSCT

| | |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------|
| End point title | Intestinal aGvHD-Free Survival After Allo-HSCT |
| End point description: Intestinal aGvHD Free Survival is the time from the date of first study drug administration (Day-1) to intestinal aGvHD event/death, where an event is defined as death due to any cause or Stage 1-4 intestinal involvement per Acute Graft versus-Host Disease Clinical Stage criteria. Data was censored for participants who have not had the intestinal aGvHD event or died or have had the event after pre-specified timing, e.g., last contact or Day +180 after allo HSCT whichever occurs first. FAS included all participants who were randomized, received at least 1 dose of the treatment, and under-went allo HSCT. 99 indicates that median was not estimable due to fewer number of participants with events. | |
| End point type | Primary |
| End point timeframe: From the date of first dose of study drug to first documented intestinal aGvHD or death, whichever occurs first up to Day +180 | |

| End point values | Placebo | Vedolizumab 300 mg | | |
|-------------------------------|-----------------|--------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 165 | 168 | | |
| Units: days | | | | |
| median (full range (min-max)) | 99 (14 to 182) | 99 (2 to 182) | | |

Statistical analyses

| | |
|-----------------------------------------|------------------------------|
| Statistical analysis title | Statistical Analysis 1 |
| Comparison groups | Vedolizumab 300 mg v Placebo |
| Number of subjects included in analysis | 333 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.001 |
| Method | Logrank |
| Parameter estimate | Hazard ratio (HR) |
| Point estimate | 0.45 |

| | |
|---------------------|---------|
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.27 |
| upper limit | 0.73 |

Secondary: Intestinal aGvHD-Free and Relapse-Free Survival

| | |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------|
| End point title | Intestinal aGvHD-Free and Relapse-Free Survival |
| End point description: | |
| GvHD and Relapse Free Survival is the time from the date of first study drug administration (Day-1) to GvHD event/death/relapse, where an event is defined as death or aGvHD Grade 3-4 by modified Glucksberg criteria or chronic GvHD requiring system immunosuppression or relapse. Data was censored for participants who have not had the event or have had the event after pre-specified timing, e.g., last contact or Day +180 after allo HSCT whichever occurs first. FAS included all participants who were randomized, received at least 1 dose of the treatment, and under-went allo HSCT. 99 indicates that median was not estimable due to fewer number of participants with events. | |
| End point type | Secondary |
| End point timeframe: | |
| From the date of first dose of study drug to first documented intestinal aGvHD or death, whichever occurs first up to Day +180 | |

| End point values | Placebo | Vedolizumab 300 mg | | |
|-------------------------------|-----------------|--------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 165 | 168 | | |
| Units: days | | | | |
| median (full range (min-max)) | 99 (13 to 182) | 99 (17 to 182) | | |

Statistical analyses

| | |
|-----------------------------------------|------------------------------|
| Statistical analysis title | Statistical Analysis 1 |
| Comparison groups | Vedolizumab 300 mg v Placebo |
| Number of subjects included in analysis | 333 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.0243 |
| Method | Logrank |
| Parameter estimate | Hazard ratio (HR) |
| Point estimate | 0.61 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.39 |
| upper limit | 0.96 |

Secondary: Grade C-D aGvHD-Free Survival

| | |
|-----------------|-------------------------------|
| End point title | Grade C-D aGvHD-Free Survival |
|-----------------|-------------------------------|

End point description:

GvHD and Relapse Free Survival is the time from the date of first study drug administration (Day-1) to GvHD event/death/relapse, where an event is defined as death or aGvHD Grade 3-4 by modified Glucksberg criteria or chronic GvHD requiring system immunosuppression or relapse. Data was censored for participants who have not had the event or have had the event after pre-specified timing, e.g., last contact or Day +180 after allo HSCT whichever occurs first. FAS included all participants who were randomized, received at least 1 dose of the treatment, and under-went allo HSCT. 99 indicates that median was not estimable due to fewer number of participants with events.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From the date of first dose of study drug to first documented intestinal aGvHD or death, whichever occurs first up to Day +180

| End point values | Placebo | Vedolizumab 300 mg | | |
|-------------------------------|-----------------|--------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 165 | 168 | | |
| Units: days | | | | |
| median (full range (min-max)) | 99 (12 to 182) | 99 (12 to 182) | | |

Statistical analyses

| Statistical analysis title | Statistical Analysis 1 |
|-----------------------------------------|------------------------------|
| Comparison groups | Vedolizumab 300 mg v Placebo |
| Number of subjects included in analysis | 333 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.0204 |
| Method | Logrank |
| Parameter estimate | Hazard ratio (HR) |
| Point estimate | 0.59 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.39 |
| upper limit | 0.91 |

Secondary: Nonrelapse Mortality (NRM)

| | |
|-----------------|----------------------------|
| End point title | Nonrelapse Mortality (NRM) |
|-----------------|----------------------------|

End point description:

Non-relapse mortality is the time from the date of first study drug administration (Day-1) to death without occurrence of a relapse. Data was censored for participants who have not had the event or have had the event after pre-specified timing, e.g., last contact or Day +180 after allo HSCT whichever occurs first. FAS included all participants who were randomized, received at least 1 dose of the treatment, and under-went allo HSCT. 99 indicates that median was not estimable due to fewer number of participants with events.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From the date of first dose of study drug to first documented intestinal aGvHD or death, whichever occurs first up to Day +180

| End point values | Placebo | Vedolizumab 300 mg | | |
|-------------------------------|-----------------|--------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 165 | 168 | | |
| Units: days | | | | |
| median (full range (min-max)) | 99 (14 to 182) | 99 (19 to 182) | | |

Statistical analyses

| Statistical analysis title | Statistical Analysis 1 |
|-----------------------------------------|------------------------------|
| Comparison groups | Vedolizumab 300 mg v Placebo |
| Number of subjects included in analysis | 333 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.0668 |
| Method | Logrank |
| Parameter estimate | Hazard ratio (HR) |
| Point estimate | 0.48 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.22 |
| upper limit | 1.04 |

Secondary: Overall Survival (OS)

| | |
|-----------------|-----------------------|
| End point title | Overall Survival (OS) |
|-----------------|-----------------------|

End point description:

Overall Survival by Days +180 is the time from the date of first study drug administration (Day-1) to death from any cause. Data was censored for participants who have not had the event or have had the event after pre-specified timing, e.g., last contact or Day +180 after allo-HSCT whichever occurs first. FAS included all participants who were randomized, received at least 1 dose of the treatment, and under-went allo HSCT. 99 indicates that median was not estimable due to fewer number of participants with events.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From the date of first dose of study drug to first documented intestinal aGvHD or death, whichever occurs first up to Day +180

| End point values | Placebo | Vedolizumab 300 mg | | |
|-------------------------------|-----------------|--------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 165 | 168 | | |
| Units: days | | | | |
| median (full range (min-max)) | 99 (14 to 182) | 99 (19 to 182) | | |

Statistical analyses

| Statistical analysis title | Statistical Analysis 1 |
|-----------------------------------------|------------------------------|
| Comparison groups | Vedolizumab 300 mg v Placebo |
| Number of subjects included in analysis | 333 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.1458 |
| Method | Logrank |
| Parameter estimate | Hazard ratio (HR) |
| Point estimate | 0.63 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.34 |
| upper limit | 1.17 |

Secondary: Grade B-D aGvHD-Free Survival

| | |
|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Grade B-D aGvHD-Free Survival |
| End point description: | Grade B-D aGvHD Survival is the time from the date of first study drug administration (Day-1) to aGvHD event or death, where an event is defined as death or grade B-D any organ involvement per IBMTR Severity Index for aGvHD. Data was censored for participants who have not had the event or have had the event after pre-specified timing, e.g., last contact or Day +180 after allo HSCT whichever occurs first. FAS included all participants who were randomized, received at least 1 dose of the treatment, and under-went allo HSCT. 99 indicates that median was not estimable due to fewer number of participants with events. |
| End point type | Secondary |
| End point timeframe: | From the date of first dose of study drug to first documented intestinal aGvHD or death, whichever occurs first up to Day +180 |

| | | | | |
|-------------------------------|-----------------|-----------------------|--|--|
| End point values | Placebo | Vedolizumab 300 mg | | |
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 165 | 168 | | |
| Units: days | | | | |
| median (full range (min-max)) | 99 (12 to 182) | 99 (12 to 182) | | |

Statistical analyses

| | |
|-----------------------------------------|------------------------------|
| Statistical analysis title | Statistical Analysis 1 |
| Comparison groups | Vedolizumab 300 mg v Placebo |
| Number of subjects included in analysis | 333 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.0105 |
| Method | Logrank |
| Parameter estimate | Hazard ratio (HR) |
| Point estimate | 0.64 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.46 |
| upper limit | 0.91 |

Adverse events

Adverse events information

Timeframe for reporting adverse events:

From the first dose of study drug until the end of study (up to approximately 281 days)

Adverse event reporting additional description:

At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment. Safety Population included all participants who received at least 1 dose of study drug.

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

| | |
|--------------------|------|
| Dictionary version | 25.0 |
|--------------------|------|

Reporting groups

| | |
|-----------------------|---------|
| Reporting group title | Placebo |
|-----------------------|---------|

Reporting group description:

Vedolizumab placebo-matching, intravenous (IV) infusion, once on Day -1 along with background graft-versus-host disease (GvHD) prophylaxis regimen prior to Allo-HSCT and once on Days +13, +41, +69, +97, +125, and +153 post Allo-HSCT.

| | |
|-----------------------|--------------------|
| Reporting group title | Vedolizumab 300 mg |
|-----------------------|--------------------|

Reporting group description:

Vedolizumab 300 mg, IV, once on Day -1 along with background graft-versus-host disease (GvHD) prophylaxis regimen prior to Allo-HSCT and once on Days +13, +41, +69, +97, +125, and +153 post Allo-HSCT.

| Serious adverse events | Placebo | Vedolizumab 300 mg | |
|---------------------------------------------------------------------|--------------------|--------------------|--|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 114 / 165 (69.09%) | 120 / 169 (71.01%) | |
| number of deaths (all causes) | 27 | 21 | |
| number of deaths resulting from adverse events | 0 | 0 | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Diffuse large B-cell lymphoma recurrent | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 2 / 169 (1.18%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Minimal residual disease | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 0 / 169 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| T-cell lymphoma recurrent | | | |

| | | | |
|---------------------------------------------------|-----------------|-----------------|--|
| subjects affected / exposed | 2 / 165 (1.21%) | 0 / 169 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 2 | 0 / 0 | |
| Acute lymphocytic leukaemia recurrent | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 3 / 169 (1.78%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Central nervous system leukaemia | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Philadelphia positive acute lymphocytic leukaemia | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 0 / 169 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Chronic myeloid leukaemia recurrent | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 3 / 169 (1.78%) | |
| occurrences causally related to treatment / all | 0 / 1 | 1 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Acute myeloid leukaemia recurrent | | | |
| subjects affected / exposed | 9 / 165 (5.45%) | 9 / 169 (5.33%) | |
| occurrences causally related to treatment / all | 0 / 13 | 0 / 10 | |
| deaths causally related to treatment / all | 0 / 4 | 0 / 1 | |
| Chloroma | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 2 / 169 (1.18%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Lymphoma | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 0 / 169 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Post transplant lymphoproliferative disorder | | | |

| | | | |
|--------------------------------------------------|-----------------|-----------------|--|
| subjects affected / exposed | 2 / 165 (1.21%) | 0 / 169 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Myelodysplastic syndrome | | | |
| subjects affected / exposed | 3 / 165 (1.82%) | 5 / 169 (2.96%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 6 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 1 | |
| Myelofibrosis | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Adenoma benign | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 0 / 169 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Peripheral T-cell lymphoma unspecified recurrent | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vascular disorders | | | |
| Shock haemorrhagic | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Venoocclusive disease | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Jugular vein thrombosis | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 0 / 169 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypertension | | | |

| | | | |
|------------------------------------------------------|------------------|------------------|--|
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hypotension | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 2 / 169 (1.18%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| General disorders and administration site conditions | | | |
| Asthenia | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Fatigue | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Malaise | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hyperthermia | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 0 / 169 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pyrexia | | | |
| subjects affected / exposed | 13 / 165 (7.88%) | 13 / 169 (7.69%) | |
| occurrences causally related to treatment / all | 0 / 15 | 1 / 15 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Multiple organ dysfunction syndrome | | | |
| subjects affected / exposed | 3 / 165 (1.82%) | 5 / 169 (2.96%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 5 | |
| deaths causally related to treatment / all | 0 / 3 | 0 / 5 | |
| Disease progression | | | |

| | | | |
|-------------------------------------------------|------------------|-----------------|--|
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Influenza like illness | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Chest pain | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Chest discomfort | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 0 / 169 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Polyserositis | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Perforated ulcer | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 0 / 169 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Immune system disorders | | | |
| Acute graft versus host disease in intestine | | | |
| subjects affected / exposed | 16 / 165 (9.70%) | 6 / 169 (3.55%) | |
| occurrences causally related to treatment / all | 1 / 20 | 1 / 6 | |
| deaths causally related to treatment / all | 0 / 2 | 0 / 0 | |
| Acute graft versus host disease in liver | | | |
| subjects affected / exposed | 2 / 165 (1.21%) | 5 / 169 (2.96%) | |
| occurrences causally related to treatment / all | 1 / 3 | 0 / 7 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 1 | |
| Acute graft versus host disease | | | |

| | | | |
|-----------------------------------------------------|-----------------|-----------------|--|
| subjects affected / exposed | 5 / 165 (3.03%) | 2 / 169 (1.18%) | |
| occurrences causally related to treatment / all | 0 / 5 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Acute graft versus host disease in skin | | | |
| subjects affected / exposed | 4 / 165 (2.42%) | 3 / 169 (1.78%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Chronic graft versus host disease | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 2 / 169 (1.18%) | |
| occurrences causally related to treatment / all | 0 / 1 | 1 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Chronic graft versus host disease in liver | | | |
| subjects affected / exposed | 2 / 165 (1.21%) | 0 / 169 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Engraftment syndrome | | | |
| subjects affected / exposed | 2 / 165 (1.21%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Graft versus host disease in eye | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Graft versus host disease in gastrointestinal tract | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Acute graft versus host disease oral | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 0 / 169 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Chronic graft versus host disease in | | | |

| | | | |
|-------------------------------------------------|-----------------|-----------------|--|
| lung | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Chronic graft versus host disease in skin | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Chronic graft versus host disease oral | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 0 / 169 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Graft versus host disease in lung | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Respiratory distress | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 0 / 169 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bronchiolitis obliterans syndrome | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 0 / 169 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bronchospasm | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pneumonitis | | | |

| | | | |
|-------------------------------------------------|-----------------|-----------------|--|
| subjects affected / exposed | 3 / 165 (1.82%) | 2 / 169 (1.18%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Epiglottic oedema | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cough | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Idiopathic pneumonia syndrome | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Interstitial lung disease | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 0 / 169 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Pulmonary alveolar haemorrhage | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pharyngeal oedema | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pleural effusion | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 2 / 169 (1.18%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pneumothorax | | | |

| | | | |
|-------------------------------------------------|-----------------|-----------------|--|
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Acute respiratory distress syndrome | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 2 / 169 (1.18%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Respiratory failure | | | |
| subjects affected / exposed | 3 / 165 (1.82%) | 5 / 169 (2.96%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 6 | |
| deaths causally related to treatment / all | 0 / 2 | 0 / 3 | |
| Acute Respiratory failure | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 0 / 169 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Psychiatric disorders | | | |
| Confusional state | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 2 / 169 (1.18%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Delirium | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 3 / 169 (1.78%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Mental status changes | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Investigations | | | |
| Pseudomonas test positive | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Blast cell count increased | | | |

| | | | |
|-------------------------------------------------|-----------------|-----------------|--|
| subjects affected / exposed | 1 / 165 (0.61%) | 0 / 169 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Alanine aminotransferase increased | | | |
| subjects affected / exposed | 4 / 165 (2.42%) | 9 / 169 (5.33%) | |
| occurrences causally related to treatment / all | 1 / 4 | 1 / 10 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Aspartate aminotransferase increased | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 2 / 169 (1.18%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Blood bilirubin increased | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 2 / 169 (1.18%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Alanine aminotransferase abnormal | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 0 / 169 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Liver function test abnormal | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 0 / 169 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Blood alkaline phosphatase increased | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Neutrophil count decreased | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Injury, poisoning and procedural complications | | | |

| | | | |
|-------------------------------------------------|-----------------|-----------------|--|
| Subdural haematoma | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Subdural haemorrhage | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 0 / 169 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Fall | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Wound dehiscence | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Prescribed overdose | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Head injury | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Engraft failure | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 4 / 169 (2.37%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Transplant failure | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 3 / 169 (1.78%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Delayed engraftment | | | |

| | | | |
|-------------------------------------------------|-----------------|-----------------|--|
| subjects affected / exposed | 1 / 165 (0.61%) | 0 / 169 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cardiac disorders | | | |
| Cardiac failures | | | |
| subjects affected / exposed | 2 / 165 (1.21%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Cardiopulmonary failure | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 0 / 169 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Myocardial infarction | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 0 / 169 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Acute myocardial infarction | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 0 / 169 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Myocarditis | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pericardial effusion | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Tachycardia | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 0 / 169 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Atrial flutter | | | |

| | | | |
|-------------------------------------------------|-----------------|-----------------|--|
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Supraventricular tachycardia | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cardiac arrest | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Ventricular tachycardia | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Nervous system disorders | | | |
| Hemorrhage intracranial | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ischaemic stroke | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Ataxia | | | |
| subjects affected / exposed | 2 / 165 (1.21%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cerebral venous sinus thrombosis | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 0 / 169 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Altered state of consciousness | | | |

| | | | |
|-------------------------------------------------|-----------------|-----------------|--|
| subjects affected / exposed | 1 / 165 (0.61%) | 0 / 169 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Syncope | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Encephalopathy | | | |
| subjects affected / exposed | 2 / 165 (1.21%) | 0 / 169 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Facial paralysis | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 0 / 169 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Posterior reversible encephalopathy syndrome | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Presyncope | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Seizure | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Epilepsy | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Partial seizures | | | |

| | | | |
|-------------------------------------------------|-----------------|-----------------|--|
| subjects affected / exposed | 1 / 165 (0.61%) | 0 / 169 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Neuralgia | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 3 / 165 (1.82%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Leukopenias | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pancytopenia | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 5 / 169 (2.96%) | |
| occurrences causally related to treatment / all | 0 / 1 | 1 / 5 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Aplastic anaemia | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Febrile neutropenia | | | |
| subjects affected / exposed | 8 / 165 (4.85%) | 7 / 169 (4.14%) | |
| occurrences causally related to treatment / all | 0 / 10 | 0 / 11 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Thrombocytopenia | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 0 / 169 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ear and labyrinth disorders | | | |

| | | | |
|-------------------------------------------------|-----------------|-----------------|--|
| Vertigo positional | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 0 / 169 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastrointestinal disorders | | | |
| Neutropenic colitis | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Diarrhoea | | | |
| subjects affected / exposed | 4 / 165 (2.42%) | 6 / 169 (3.55%) | |
| occurrences causally related to treatment / all | 1 / 4 | 0 / 6 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Abdominal pain | | | |
| subjects affected / exposed | 4 / 165 (2.42%) | 2 / 169 (1.18%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Oesophageal food impaction | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Lower gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 0 / 169 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Nausea | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 2 / 169 (1.18%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vomiting | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 4 / 169 (2.37%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastrointestinal haemorrhage | | | |

| | | | |
|-------------------------------------------------|-----------------|-----------------|--|
| subjects affected / exposed | 1 / 165 (0.61%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Stomatitis | | | |
| subjects affected / exposed | 4 / 165 (2.42%) | 5 / 169 (2.96%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 6 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Upper gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 0 / 169 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hepatobiliary disorders | | | |
| Hyperbilirubinaemia | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Choleostasis | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 0 / 169 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Liver disorder | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hepatic function abnormal | | | |
| subjects affected / exposed | 4 / 165 (2.42%) | 2 / 169 (1.18%) | |
| occurrences causally related to treatment / all | 2 / 4 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hepatic failure | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 0 / 169 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Autoimmune hepatitis | | | |

| | | | |
|-------------------------------------------------|-----------------|-----------------|--|
| subjects affected / exposed | 1 / 165 (0.61%) | 0 / 169 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Skin and subcutaneous tissue disorders | | | |
| Rash macular | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 0 / 169 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Palmar-plantar erythrodysaesthesia syndrome | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Renal and urinary disorders | | | |
| Micturition urgency | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Nephrotic syndrome | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 0 / 169 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Nephropathy toxic | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cystitis haemorrhagic | | | |
| subjects affected / exposed | 2 / 165 (1.21%) | 4 / 169 (2.37%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Renal failure | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

| | | | |
|-------------------------------------------------|-----------------|-----------------|--|
| Acute kidney injury | | | |
| subjects affected / exposed | 8 / 165 (4.85%) | 3 / 169 (1.78%) | |
| occurrences causally related to treatment / all | 0 / 9 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Prerenal failure | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 0 / 169 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Renal impairment | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Haematuria | | | |
| subjects affected / exposed | 2 / 165 (1.21%) | 0 / 169 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Musculoskeletal and connective tissue disorders | | | |
| Pain in jaw | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bone pain | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 0 / 169 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Osteonecrosis | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Rotator cuff syndrome | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 0 / 169 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

| | | | |
|-------------------------------------------------|-----------------|-----------------|--|
| Muscular weakness | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 0 / 169 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Infections and infestations | | | |
| Enterocolitis infectious | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 2 / 169 (1.18%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Diverticulitis | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 0 / 169 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastroenteritis | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Atypical mycobacterial infection | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 0 / 169 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bronchopulmonary aspergillosis | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Acinetobacter infection | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 0 / 169 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Anorectal cellulitis | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 0 / 169 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bacterial infection | | | |

| | | | |
|-------------------------------------------------|-----------------|-----------------|--|
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Systemic candida | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 2 / 169 (1.18%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Encephalitis | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 0 / 169 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Extradural abscess | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| COVID-19 | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Clostridium difficile infection | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 2 / 169 (1.18%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cytomegalovirus infection reactivation | | | |
| subjects affected / exposed | 2 / 165 (1.21%) | 6 / 169 (3.55%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 8 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cytomegalovirus colitis | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 0 / 169 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cytomegalovirus infection | | | |

| | | | |
|-------------------------------------------------|-----------------|-----------------|--|
| subjects affected / exposed | 0 / 165 (0.00%) | 2 / 169 (1.18%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Epstein-Barr virus infection reactivation | | | |
| subjects affected / exposed | 2 / 165 (1.21%) | 0 / 169 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Escherichia bacteraemia | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 2 / 169 (1.18%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Escherichia sepsis | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 0 / 169 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Escherichia infection | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Fungal infection | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Sinusitis fungal | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 0 / 169 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Herpes zoster | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 2 / 169 (1.18%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Human herpesvirus 6 encephalitis | | | |

| | | | |
|-------------------------------------------------|-----------------|-----------------|--|
| subjects affected / exposed | 1 / 165 (0.61%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Infection | | | |
| subjects affected / exposed | 2 / 165 (1.21%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Respiratory tract infection | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| Wound infection | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Klebsiella bacteraemia | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pneumonia | | | |
| subjects affected / exposed | 8 / 165 (4.85%) | 5 / 169 (2.96%) | |
| occurrences causally related to treatment / all | 1 / 8 | 1 / 7 | |
| deaths causally related to treatment / all | 0 / 2 | 0 / 2 | |
| Klebsiella sepsis | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Tracheobronchitis | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Atypical pneumonia | | | |

| | | | |
|-------------------------------------------------|-----------------|-----------------|--|
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bronchitis | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Lung abscess | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Epididymitis | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pneumocystis jirovecii pneumonia | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 0 / 169 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| BK virus infection | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 0 / 169 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Human polyomavirus infection | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 0 / 169 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pneumonia pseudomonal | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Respiratory syncytial virus infection | | | |

| | | | |
|-------------------------------------------------|-----------------|-----------------|--|
| subjects affected / exposed | 1 / 165 (0.61%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Respiratory syncytial virus bronchitis | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Rhinovirus infection | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 0 / 169 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Sepsis | | | |
| subjects affected / exposed | 9 / 165 (5.45%) | 4 / 169 (2.37%) | |
| occurrences causally related to treatment / all | 1 / 13 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 3 | 0 / 0 | |
| Bacteraemia | | | |
| subjects affected / exposed | 5 / 165 (3.03%) | 0 / 169 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 5 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Septic shock | | | |
| subjects affected / exposed | 4 / 165 (2.42%) | 4 / 169 (2.37%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Device related sepsis | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 0 / 169 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Neutropenic sepsis | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 0 / 169 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Septic embolus | | | |

| | | | |
|-------------------------------------------------|-----------------|-----------------|--|
| subjects affected / exposed | 1 / 165 (0.61%) | 0 / 169 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Septic encephalopathy | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| Skin infection | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Staphylococcal bacteraemia | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Staphylococcal sepsis | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cerebral toxoplasmosis | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Urinary tract infection | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vascular device infection | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Meningitis viral | | | |

| | | | |
|-------------------------------------------------|-----------------|-----------------|--|
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Viral infection | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Metabolism and nutrition disorders | | | |
| Metabolic acidosis | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 0 / 169 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hyperglycaemia | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 2 / 169 (1.18%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Failure to thrive | | | |
| subjects affected / exposed | 2 / 165 (1.21%) | 0 / 169 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hyperkalaemia | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 7 | 0 / 12 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hyponatraemia | | | |
| subjects affected / exposed | 0 / 165 (0.00%) | 1 / 169 (0.59%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Dehydration | | | |
| subjects affected / exposed | 1 / 165 (0.61%) | 2 / 169 (1.18%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

Frequency threshold for reporting non-serious adverse events: 5 %

| Non-serious adverse events | Placebo | Vedolizumab 300 mg | |
|-------------------------------------------------------|--------------------|---------------------|--|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 164 / 165 (99.39%) | 169 / 169 (100.00%) | |
| Vascular disorders | | | |
| Hypertension | | | |
| subjects affected / exposed | 54 / 165 (32.73%) | 54 / 169 (31.95%) | |
| occurrences (all) | 65 | 63 | |
| Hypotension | | | |
| subjects affected / exposed | 12 / 165 (7.27%) | 19 / 169 (11.24%) | |
| occurrences (all) | 13 | 21 | |
| General disorders and administration site conditions | | | |
| Pyrexia | | | |
| subjects affected / exposed | 62 / 165 (37.58%) | 80 / 169 (47.34%) | |
| occurrences (all) | 95 | 129 | |
| Fatigue | | | |
| subjects affected / exposed | 50 / 165 (30.30%) | 38 / 169 (22.49%) | |
| occurrences (all) | 64 | 51 | |
| Oedema Peripheral | | | |
| subjects affected / exposed | 35 / 165 (21.21%) | 29 / 169 (17.16%) | |
| occurrences (all) | 49 | 34 | |
| Asthenia | | | |
| subjects affected / exposed | 12 / 165 (7.27%) | 14 / 169 (8.28%) | |
| occurrences (all) | 16 | 14 | |
| Chills | | | |
| subjects affected / exposed | 10 / 165 (6.06%) | 11 / 169 (6.51%) | |
| occurrences (all) | 11 | 16 | |
| Oedema | | | |
| subjects affected / exposed | 13 / 165 (7.88%) | 7 / 169 (4.14%) | |
| occurrences (all) | 15 | 7 | |
| Pain | | | |
| subjects affected / exposed | 11 / 165 (6.67%) | 4 / 169 (2.37%) | |
| occurrences (all) | 11 | 4 | |
| Immune system disorders | | | |

| | | | |
|-------------------------------------------------|-------------------|-------------------|--|
| Acute Graft Versus Host Disease in Skin | | | |
| subjects affected / exposed | 65 / 165 (39.39%) | 67 / 169 (39.64%) | |
| occurrences (all) | 81 | 84 | |
| Acute Graft Versus Host Disease In Intestine | | | |
| subjects affected / exposed | 15 / 165 (9.09%) | 10 / 169 (5.92%) | |
| occurrences (all) | 15 | 15 | |
| Chronic Graft Versus Host Disease Oral | | | |
| subjects affected / exposed | 10 / 165 (6.06%) | 14 / 169 (8.28%) | |
| occurrences (all) | 11 | 17 | |
| Chronic Graft Versus Host Disease In Skin | | | |
| subjects affected / exposed | 7 / 165 (4.24%) | 16 / 169 (9.47%) | |
| occurrences (all) | 7 | 16 | |
| Chronic Graft Versus Host Disease | | | |
| subjects affected / exposed | 12 / 165 (7.27%) | 10 / 169 (5.92%) | |
| occurrences (all) | 12 | 10 | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Cough | | | |
| subjects affected / exposed | 25 / 165 (15.15%) | 26 / 169 (15.38%) | |
| occurrences (all) | 30 | 27 | |
| Oropharyngeal Pain | | | |
| subjects affected / exposed | 16 / 165 (9.70%) | 25 / 169 (14.79%) | |
| occurrences (all) | 16 | 27 | |
| Dyspnoea | | | |
| subjects affected / exposed | 22 / 165 (13.33%) | 16 / 169 (9.47%) | |
| occurrences (all) | 28 | 18 | |
| Epistaxis | | | |
| subjects affected / exposed | 17 / 165 (10.30%) | 18 / 169 (10.65%) | |
| occurrences (all) | 18 | 25 | |
| Dyspnoea Exertional | | | |
| subjects affected / exposed | 15 / 165 (9.09%) | 7 / 169 (4.14%) | |
| occurrences (all) | 16 | 10 | |
| Rhinorrhoea | | | |
| subjects affected / exposed | 9 / 165 (5.45%) | 12 / 169 (7.10%) | |
| occurrences (all) | 10 | 14 | |

| | | | |
|----------------------------------------------------------------------------------------|-------------------------|-------------------------|--|
| Pneumonia subjects affected / exposed occurrences (all) | 9 / 165 (5.45%) 9 | 9 / 169 (5.33%) 9 | |
| Hypoxia subjects affected / exposed occurrences (all) | 11 / 165 (6.67%) 13 | 7 / 169 (4.14%) 9 | |
| Productive Cough subjects affected / exposed occurrences (all) | 9 / 165 (5.45%) 9 | 6 / 169 (3.55%) 6 | |
| Nasopharyngitis subjects affected / exposed occurrences (all) | 4 / 165 (2.42%) 6 | 9 / 169 (5.33%) 11 | |
| Psychiatric disorders | | | |
| Insomnia subjects affected / exposed occurrences (all) | 32 / 165 (19.39%) 35 | 35 / 169 (20.71%) 36 | |
| Anxiety subjects affected / exposed occurrences (all) | 14 / 165 (8.48%) 14 | 14 / 169 (8.28%) 15 | |
| Depression subjects affected / exposed occurrences (all) | 6 / 165 (3.64%) 6 | 13 / 169 (7.69%) 15 | |
| Confusional State subjects affected / exposed occurrences (all) | 10 / 165 (6.06%) 10 | 3 / 169 (1.78%) 3 | |
| Investigations | | | |
| Platelet Count Decreased subjects affected / exposed occurrences (all) | 47 / 165 (28.48%) 56 | 38 / 169 (22.49%) 52 | |
| Alanine Aminotransferase Increased subjects affected / exposed occurrences (all) | 26 / 165 (15.76%) 34 | 36 / 169 (21.30%) 53 | |
| Blood Creatinine Increased subjects affected / exposed occurrences (all) | 35 / 165 (21.21%) 40 | 24 / 169 (14.20%) 34 | |
| Aspartate Aminotransferase Increased | | | |

| | | | |
|------------------------------------------------------------------------------------------------------------|-------------------------|-------------------------|--|
| subjects affected / exposed occurrences (all) | 25 / 165 (15.15%) 27 | 30 / 169 (17.75%) 40 | |
| Blood Bilirubin Increased subjects affected / exposed occurrences (all) | 27 / 165 (16.36%) 27 | 21 / 169 (12.43%) 25 | |
| Blood Alkaline Phosphatase Increased subjects affected / exposed occurrences (all) | 15 / 165 (9.09%) 19 | 16 / 169 (9.47%) 17 | |
| Neutrophil Count Decreased subjects affected / exposed occurrences (all) | 15 / 165 (9.09%) 19 | 13 / 169 (7.69%) 18 | |
| White Blood Cell Count Decreased subjects affected / exposed occurrences (all) | 18 / 165 (10.91%) 21 | 10 / 169 (5.92%) 13 | |
| Injury, poisoning and procedural complications Fall subjects affected / exposed occurrences (all) | 9 / 165 (5.45%) 11 | 8 / 169 (4.73%) 9 | |
| Infusion Related Reaction subjects affected / exposed occurrences (all) | 3 / 165 (1.82%) 3 | 9 / 169 (5.33%) 10 | |
| Cardiac disorders Tachycardia subjects affected / exposed occurrences (all) | 6 / 165 (3.64%) 9 | 12 / 169 (7.10%) 13 | |
| Nervous system disorders Headache subjects affected / exposed occurrences (all) | 58 / 165 (35.15%) 80 | 58 / 169 (34.32%) 76 | |
| Dizziness subjects affected / exposed occurrences (all) | 23 / 165 (13.94%) 33 | 21 / 169 (12.43%) 23 | |
| Dysgeusia subjects affected / exposed occurrences (all) | 21 / 165 (12.73%) 22 | 23 / 169 (13.61%) 25 | |
| Tremor | | | |

| | | | |
|---------------------------------------------------------------------------|---------------------------|--------------------------|--|
| subjects affected / exposed occurrences (all) | 21 / 165 (12.73%) 23 | 19 / 169 (11.24%) 21 | |
| Neuropathy Peripheral subjects affected / exposed occurrences (all) | 9 / 165 (5.45%) 10 | 10 / 169 (5.92%) 11 | |
| Blood and lymphatic system disorders | | | |
| Anaemia subjects affected / exposed occurrences (all) | 72 / 165 (43.64%) 91 | 68 / 169 (40.24%) 86 | |
| Febrile Neutropenia subjects affected / exposed occurrences (all) | 54 / 165 (32.73%) 58 | 67 / 169 (39.64%) 71 | |
| Thrombocytopenia subjects affected / exposed occurrences (all) | 31 / 165 (18.79%) 42 | 43 / 169 (25.44%) 54 | |
| Neutropenia subjects affected / exposed occurrences (all) | 32 / 165 (19.39%) 38 | 40 / 169 (23.67%) 46 | |
| Eye disorders | | | |
| Dry Eye subjects affected / exposed occurrences (all) | 21 / 165 (12.73%) 25 | 34 / 169 (20.12%) 36 | |
| Vision Blurred subjects affected / exposed occurrences (all) | 11 / 165 (6.67%) 12 | 10 / 169 (5.92%) 10 | |
| Gastrointestinal disorders | | | |
| Diarrhoea subjects affected / exposed occurrences (all) | 102 / 165 (61.82%) 141 | 95 / 169 (56.21%) 142 | |
| Stomatitis subjects affected / exposed occurrences (all) | 90 / 165 (54.55%) 102 | 90 / 169 (53.25%) 104 | |
| Nausea subjects affected / exposed occurrences (all) | 83 / 165 (50.30%) 110 | 85 / 169 (50.30%) 109 | |
| Vomiting | | | |

| | | | |
|----------------------------------------|-------------------|-------------------|--|
| subjects affected / exposed | 55 / 165 (33.33%) | 41 / 169 (24.26%) | |
| occurrences (all) | 75 | 58 | |
| Constipation | | | |
| subjects affected / exposed | 47 / 165 (28.48%) | 43 / 169 (25.44%) | |
| occurrences (all) | 53 | 48 | |
| Abdominal Pain | | | |
| subjects affected / exposed | 35 / 165 (21.21%) | 34 / 169 (20.12%) | |
| occurrences (all) | 47 | 45 | |
| Dry Mouth | | | |
| subjects affected / exposed | 28 / 165 (16.97%) | 27 / 169 (15.98%) | |
| occurrences (all) | 31 | 32 | |
| Dyspepsia | | | |
| subjects affected / exposed | 20 / 165 (12.12%) | 13 / 169 (7.69%) | |
| occurrences (all) | 22 | 13 | |
| Abdominal Pain Upper | | | |
| subjects affected / exposed | 16 / 165 (9.70%) | 16 / 169 (9.47%) | |
| occurrences (all) | 19 | 21 | |
| Abdominal Distension | | | |
| subjects affected / exposed | 11 / 165 (6.67%) | 13 / 169 (7.69%) | |
| occurrences (all) | 12 | 14 | |
| Proctalgia | | | |
| subjects affected / exposed | 15 / 165 (9.09%) | 9 / 169 (5.33%) | |
| occurrences (all) | 15 | 9 | |
| Haemorrhoids | | | |
| subjects affected / exposed | 8 / 165 (4.85%) | 14 / 169 (8.28%) | |
| occurrences (all) | 8 | 14 | |
| Gastrooesophageal Reflux Disease | | | |
| subjects affected / exposed | 12 / 165 (7.27%) | 9 / 169 (5.33%) | |
| occurrences (all) | 12 | 10 | |
| Oral Pain | | | |
| subjects affected / exposed | 7 / 165 (4.24%) | 12 / 169 (7.10%) | |
| occurrences (all) | 8 | 13 | |
| Flatulence | | | |
| subjects affected / exposed | 10 / 165 (6.06%) | 4 / 169 (2.37%) | |
| occurrences (all) | 10 | 4 | |
| Skin and subcutaneous tissue disorders | | | |

| | | | |
|-------------------------------------------------|-------------------|-------------------|--|
| Rash | | | |
| subjects affected / exposed | 36 / 165 (21.82%) | 43 / 169 (25.44%) | |
| occurrences (all) | 44 | 55 | |
| Pruritus | | | |
| subjects affected / exposed | 33 / 165 (20.00%) | 28 / 169 (16.57%) | |
| occurrences (all) | 42 | 33 | |
| Dry Skin | | | |
| subjects affected / exposed | 22 / 165 (13.33%) | 23 / 169 (13.61%) | |
| occurrences (all) | 26 | 26 | |
| Erythema | | | |
| subjects affected / exposed | 13 / 165 (7.88%) | 23 / 169 (13.61%) | |
| occurrences (all) | 17 | 32 | |
| Rash Maculo-Papular | | | |
| subjects affected / exposed | 15 / 165 (9.09%) | 18 / 169 (10.65%) | |
| occurrences (all) | 20 | 23 | |
| Urticaria | | | |
| subjects affected / exposed | 4 / 165 (2.42%) | 9 / 169 (5.33%) | |
| occurrences (all) | 4 | 9 | |
| Renal and urinary disorders | | | |
| Acute Kidney Injury | | | |
| subjects affected / exposed | 20 / 165 (12.12%) | 21 / 169 (12.43%) | |
| occurrences (all) | 21 | 24 | |
| Dysuria | | | |
| subjects affected / exposed | 12 / 165 (7.27%) | 13 / 169 (7.69%) | |
| occurrences (all) | 13 | 13 | |
| Haematuria | | | |
| subjects affected / exposed | 13 / 165 (7.88%) | 9 / 169 (5.33%) | |
| occurrences (all) | 13 | 9 | |
| Pollakiuria | | | |
| subjects affected / exposed | 7 / 165 (4.24%) | 9 / 169 (5.33%) | |
| occurrences (all) | 8 | 9 | |
| Musculoskeletal and connective tissue disorders | | | |
| Back Pain | | | |
| subjects affected / exposed | 20 / 165 (12.12%) | 36 / 169 (21.30%) | |
| occurrences (all) | 20 | 41 | |
| Arthralgia | | | |

| | | | |
|------------------------------------|-------------------|-------------------|--|
| subjects affected / exposed | 19 / 165 (11.52%) | 24 / 169 (14.20%) | |
| occurrences (all) | 25 | 34 | |
| Pain In Extremity | | | |
| subjects affected / exposed | 16 / 165 (9.70%) | 17 / 169 (10.06%) | |
| occurrences (all) | 20 | 21 | |
| Infections and infestations | | | |
| Cytomegalovirus Infection | | | |
| Reactivation | | | |
| subjects affected / exposed | 28 / 165 (16.97%) | 37 / 169 (21.89%) | |
| occurrences (all) | 40 | 48 | |
| Metabolism and nutrition disorders | | | |
| Hypomagnesaemia | | | |
| subjects affected / exposed | 52 / 165 (31.52%) | 60 / 169 (35.50%) | |
| occurrences (all) | 57 | 73 | |
| Hypokalaemia | | | |
| subjects affected / exposed | 54 / 165 (32.73%) | 47 / 169 (27.81%) | |
| occurrences (all) | 70 | 58 | |
| Decreased Appetite | | | |
| subjects affected / exposed | 40 / 165 (24.24%) | 45 / 169 (26.63%) | |
| occurrences (all) | 52 | 52 | |
| Hyperglycaemia | | | |
| subjects affected / exposed | 22 / 165 (13.33%) | 19 / 169 (11.24%) | |
| occurrences (all) | 35 | 21 | |
| Hypocalcaemia | | | |
| subjects affected / exposed | 16 / 165 (9.70%) | 22 / 169 (13.02%) | |
| occurrences (all) | 17 | 23 | |
| Hypoalbuminaemia | | | |
| subjects affected / exposed | 17 / 165 (10.30%) | 17 / 169 (10.06%) | |
| occurrences (all) | 18 | 17 | |
| Hyponatraemia | | | |
| subjects affected / exposed | 18 / 165 (10.91%) | 15 / 169 (8.88%) | |
| occurrences (all) | 21 | 15 | |
| Hypophosphataemia | | | |
| subjects affected / exposed | 14 / 165 (8.48%) | 18 / 169 (10.65%) | |
| occurrences (all) | 17 | 20 | |
| Hyperkalaemia | | | |

| | | | |
|-----------------------------|-----------------|------------------|--|
| subjects affected / exposed | 6 / 165 (3.64%) | 12 / 169 (7.10%) | |
| occurrences (all) | 7 | 12 | |
| Hypervolaemia | | | |
| subjects affected / exposed | 9 / 165 (5.45%) | 7 / 169 (4.14%) | |
| occurrences (all) | 11 | 8 | |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10 June 2019 | <p>The following is a summary of the changes made in the amendment 06:</p> <ul style="list-style-type: none">• Consolidation of the previous local amendments to meet local regulations into a single global amendment.• Addition of final results from the completed Study Vedolizumab-1015.• Clarification of the screening window and that subjects may be rescreened.• Clarification that randomization may occur within 2 days of the first dose of study drug on Day -1.• Clarification of the inclusion and exclusion criteria.• Clarification of the excluded and permitted concomitant medications.• Addition of a criterion for withdrawal of a subject from the study for lack of efficacy.• Clarification of the management of clinical events.• Clarification regarding unscheduled PK sample collection.• Clarification regarding AEs: management of clinical events, specification of AESIs, and reporting periods for collection of AEs and SAEs.• Clarification of the timing of the primary analysis for efficacy and safety.• Clarifications to the footnotes of the schedule of events to align with updates to text. |
| 18 September 2019 | <p>The following is a summary of the changes made in the amendment 07:</p> <ol style="list-style-type: none">1. Clarification of the description of the disease to be treated in adolescent subjects.2. Addition of results from nonclinical studies related to inclusion of adolescent subjects.3. Updated human experience as reported in the 9th development safety update report.4. Update to the study rationale to support the inclusion of adolescent subjects.5. Update to the benefit:risk profile to support the inclusion of adolescent subjects.6. Addition of data supporting the dose regimen in adolescent subjects.7. Update of the inclusion criteria impacted by inclusion of adolescent subjects.8. Update to permitted medications to include use of topical anesthetic in adolescent subjects.9. Clarification to the procedures to be conducted after discontinuation or withdrawal of a subject.10. Added assessment of height to be collected at the end of study visit.11. Updated the pregnancy testing and contraception requirements to include female adolescent subjects aged 12 years and greater.12. Addition of necessary age-appropriate documentation that must be completed for adolescent subjects.13. Addition of blood collection volumes for adolescent and adult subjects.14. Update to the version of Common Terminology Criteria for Adverse Events to be used for the grading of adverse events.15. Update to stratification to include age group and data assessments in adolescent subjects.16. Updates to Appendix A, Schedule of Events footnotes, to align with updates in text.17. Update to Appendix B regarding methotrexate treatment to support the inclusion of adolescent subjects.18. Update to Appendix F to include age-appropriate assessments of aGvHD clinical stage and Mount Sinai Acute GVHD International Consortium severity index for aGvHD. |

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported